Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Johnson & Johnson Acquires Atraverse Medical to Expand Cardiac Ablation Portfolio with Next-Gen Left-Heart Access Technology

Fineline Cube Apr 27, 2026
Company Deals

Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider

Fineline Cube Apr 24, 2026
Company Deals

Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market

Fineline Cube Apr 24, 2026
Company Deals Digital

SciClone Pharmaceuticals Partners with JD Healthcare to Pioneer Integrated Immune Health Management Model

Fineline Cube Apr 24, 2026
Company Deals

Mebanks Divests Guangzhou Specialty Pharmacy Subsidiary to DaShenLin for $7.75 Million to Focus on Higher-Margin Health Insurance and Management Businesses

Fineline Cube Apr 23, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

AstraZeneca Secures Dual NMPA Approvals for Imfinzi-Based Regimens in Advanced Hepatocellular Carcinoma and NSCLC

Fineline Cube Apr 27, 2026
Company Drug

China Medical System’s Comekibart Anti-IL-4Rα Antibody Enters NMPA Review for Seasonal Allergic Rhinitis

Fineline Cube Apr 24, 2026
Company Drug

YiChang HEC ChangJiang Pharma’s Insulin Aspart Gains NMPA Approval

Fineline Cube Oct 19, 2022

China-based firm YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558) has announced that its in-house...

Company Drug

Henlius Biotech’s Hanbeitai Gains NMPA Approval for Recurrent Glioblastoma

Fineline Cube Oct 19, 2022

Shanghai Henlius Biotech Inc. (HKG: 2696) has announced that a supplementary Biologic License Application (sBLA)...

Company Policy / Regulatory

NHSA Responds to Proposal on Dental Implants’ Inclusion in NRDL

Fineline Cube Oct 19, 2022

The National Healthcare Security Administration (NHSA) has responded to the No. 6184 suggestion from the...

Company

Johnson & Johnson Reports Q3 Sales Growth, Maintains Full-Year Guidance

Fineline Cube Oct 19, 2022

US giant Johnson & Johnson (J&J, NYSE: JNJ) released its Q3 2022 financial report, showing...

Company Deals

Sichuan Biokin Pharma Plans IPO on STAR Board to Raise RMB 1.422 Billion

Fineline Cube Oct 19, 2022

China-based Sichuan Biokin Pharmaceutical Co., Ltd is set to conduct an initial public offering (IPO)...

Company Drug

Mabwell Bioscience’s 9MW3011 Accepted for Review by China’s NMPA

Fineline Cube Oct 19, 2022

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that its clinical filing for...

Company Drug

Zhiyi Biotechnology Receives FDA Clearance for SK10 in Chemotherapy-Induced Diarrhea

Fineline Cube Oct 19, 2022

Guangzhou-based Zhiyi Biotechnology has announced receiving clearance from the US FDA for a clinical study...

Company Deals

Shanghai’s Hrain Biotechnology Plans IPO on STAR Board to Raise RMB 2.539 Billion

Fineline Cube Oct 19, 2022

Shanghai-based Hrain Biotechnology Co., Ltd, a specialist in tumor immunotherapy, plans to conduct an initial...

Company Deals

Eucure Biopharma Partners with Syncromune on Intratumoral Immunotherapy

Fineline Cube Oct 18, 2022

Eucure Biopharma, a wholly-owned subsidiary of Sino-US contract research organization (CRO) Biocytogen, has entered into...

Company Drug

Abogen Biosciences Receives UAE Clinical Trial Approval for Omicron BA.4/5 mRNA Vaccine

Fineline Cube Oct 18, 2022

China’s Abogen Biosciences Co., Ltd, a developer of messenger ribonucleic acid (mRNA) drugs, has announced...

Company Deals

Shenzhen GeneBioHealth Secures USD 15M for Bio-Business Expansion

Fineline Cube Oct 18, 2022

Shenzhen GeneBioHealth Co., Ltd, a China-based in-vitro diagnostic (IVD) medical device developer, has reportedly raised...

Company Drug

CSPC’s Generic Xofluza Gains NMPA Approval Amid Roche Patent Dispute

Fineline Cube Oct 18, 2022

China-based CSPC Pharmaceutical Group Co., Ltd (HKG: 1093) has obtained market approval from the National...

Company Drug

Gracell Biotechnologies Initiates Phase II Dosing for GC007g in B-ALL Patients

Fineline Cube Oct 18, 2022

China-based Gracell Biotechnologies Inc. has announced the first patient dosing in the Phase II portion...

Company Drug

Henlius Biotech Gains NMPA Approval for Phase I Trial of HLX60 in Solid Tumors and Lymphomas

Fineline Cube Oct 18, 2022

Shanghai Henlius Biotech Inc. (HKG: 2696) has announced receiving approval from the National Medical Products...

Company Deals

PureID Medical Technology Secures RMB 100M Series B Funding

Fineline Cube Oct 18, 2022

PureID Medical Technology Co., Ltd, a medical device compliance service provider based in Guangzhou, has...

Company Drug

Sinocelltech’s COVID-19 Vaccines SCTV01C and SCTV01E Show Promising Phase III Results

Fineline Cube Oct 18, 2022

China-based Sinocelltech Group Ltd (SHA: 688520) has announced the preliminary interim analysis results of a...

Company Drug

Jemincare’s Sonidegib Receives First Prescriptions in China for Basal Cell Carcinoma

Fineline Cube Oct 18, 2022

China-based Jiangxi Jemincare Group has announced the first prescriptions in China for its sonidegib, a...

Company Deals

Salus Biomed Raises Over RMB 100M in Pre-Series A Financing

Fineline Cube Oct 18, 2022

Salus Biomed, a sequencing and spatial omics platform provider based in Guangdong, has reportedly raised...

Company Drug

Haisco Pharma’s Ciprofol Injection Gains NMPA Approval for Gynecology Use

Fineline Cube Oct 18, 2022

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced receiving another marketing approval from...

Company Drug

ScienCare Pharma’s Naltrexone Implant Prioritized for Review by CDE

Fineline Cube Oct 18, 2022

The Center for Drug Evaluation (CDE) website indicates that the market filing by China-based Shenzhen...

Posts pagination

1 … 604 605 606 … 656

Recent updates

  • Johnson & Johnson Acquires Atraverse Medical to Expand Cardiac Ablation Portfolio with Next-Gen Left-Heart Access Technology
  • NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting
  • Sun Pharma to Acquire Organon for $11.75 Billion, Creating Global Top-25 Pharmaceutical Leader in Branded Generics
  • AstraZeneca Secures Dual NMPA Approvals for Imfinzi-Based Regimens in Advanced Hepatocellular Carcinoma and NSCLC
  • Insilico Medicine Advances AI-Designed PRMT5 Inhibitor ISM0387 for Glioblastoma with Sub-12-Month Discovery Timeline
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Johnson & Johnson Acquires Atraverse Medical to Expand Cardiac Ablation Portfolio with Next-Gen Left-Heart Access Technology

Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Others

Sun Pharma to Acquire Organon for $11.75 Billion, Creating Global Top-25 Pharmaceutical Leader in Branded Generics

Company Drug

AstraZeneca Secures Dual NMPA Approvals for Imfinzi-Based Regimens in Advanced Hepatocellular Carcinoma and NSCLC

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.